Patent ID: 7618632
Filing Date: 2009-11-17
Classification: A61K,A61P,C07K,G01N

Abstract:
1. A method of treating or ameliorating an immune cell-associated pathology in a subject for whom suppression of immune response is desired, wherein the immune cell is a T cell, comprising administering to the subject a therapeutically effective amount of a neutralizing anti-Glucocorticoid-Induced TNF Receptor Ligand antibody (anti-GITRL antibody), wherein the anti-GITRL antibody is a 5F1 antibody, a 10F12 antibody, or an antigen-binding fragment thereof, and wherein the anti-GITRL antibody treats or ameliorates the immune cell-associated pathology by blocking GITRL binding to the Glucocorticoid-Induced TNF Receptor (GITR) on effector T cells, and wherein the immune cell-associated pathology is selected from the group consisting of rheumatoid arthritis, encephalomyelitis, multiple sclerosis, osteoarthritis, autoimmune gastritis, psoriasis and other inflammatory dermatoses, asthma, allergy, organ transplant rejection, graft-versus-host disease, and inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.